HERMA, a manufacturer of precision labelling machines for a variety of sectors, will showcase a quartet of high-performance labelling solutions at Pack Expo Las Vegas, 29th September - 1st October.
Aptamer Group has announced the launch of its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development an innovative approach to identify and validate new disease markers.
Europa Biosite has announced that Bio X Cell has appointed Cambridge Bioscience, a member of Europa Biosite, as its exclusive distributor for the United Kingdom and Ireland.
Eppendorf has announced the commercial launch of the Eppendorf Research 3 neo, designed to deliver accurate and precise results for accelerated volume selection, and optimised ergonomics.
The pharmaceutical industry continues to evolve, adopting new technologies and optimising resources and expertise to meet authentication and anti-counterfeiting challenges, says Dr Mark Deakes, chairman of the IOTA.
Gifthealth has announced its acquisition of Occam Health Services creating the "first-of-its-kind" digital pharmacy platform and patient access hub solution.
Lubrizol will showcase the benefits of its polymer-based excipients for the solubility, bioavailability and palatability of APIs and nutraceuticals at CPHI Frankfurt (28th- 30th October 2025 at Stand 8.0M71).
Polpharma Biologics has announced that it has signed licensing agreements with MS Pharma for the commercialisation of its biosimilar candidates vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) in the MENA region.
CN Bio, a provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, has announced the expansion of its Contract Research Services (CRS) with new PhysioMimix computational modelling tools.
TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, has announced the formation of its Scientific Advisory Board (SAB).
Aptamer, the developer of next-generation synthetic binders for the life sciences industry, has announced that it has signed a new therapeutic development agreement with Invizius.
